Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Proactive - Interviews for investors

Proactive - Interviews for investors artwork

XanaMIA results: What's next for Actinogen Medical?

Nov 20, 20266 minAudioEpisode 15124
ShareXLinkedInFacebookWhatsAppEmail

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged over 75, although the primary endpoint was not achieved across the overall trial population. Gourlay highlighted a statistically significant difference in complete disease stabilisation among older participants, with 40% of patients receiving Xanamem showing no disease progression compared with 22% in the placebo group. The CEO also discussed the reported 30% slowing of Alzheimer's disease progression among patients older than 75, comparing the results with those observed for intravenous antibody therapies. Gourlay explained why the stronger response in older patients could be consistent with Xanamem's mechanism of action, which targets an enzyme involved in cortisol production in the brain. Looking ahead, Actinogen Medical is continuing its open-label extension study, with an expanded dataset expected in early 2027. Gourlay discussed the encouraging preliminary observations from 29 participants and the company's plans to assess results from at least 100 patients. With A$18.9 million in cash, Actinogen Medical also intends to engage with potential pharmaceutical development partners and regulators before committing further expenditure to a Phase 3 programme. Watch the full interview to hear Dr Steven Gourlay explain the XanaMIA results, the opportunity in older Alzheimer's patients and the potential next steps for Xanamem. For more biotechnology, healthcare and ASX company interviews, visit Proactive's YouTube channel. Give this video a like, subscribe to the channel and enable notifications so you don't miss future updates. #ActinogenMedical #AlzheimersDisease #Xanamem #XanaMIA #AlzheimersResearch #ClinicalTrials #Biotechnology #DrugDevelopment #ASXACW #HealthcareStocks #Phase3Trials #Neuroscience #ProactiveInvestors

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Saturna Capital analyst flags global AI opportunities and risks of soaring investment

    Nov 20, 20267 minAudio

    Saturna Capital senior investment analyst and portfolio manager Levi Stewart Zurbrugg talked with Proactive's Stephen Gunnion about global equity opportunities, the international AI supply chain, rising interest rates...

    Credit the people on this episode

  2. Sprott Asset Management's Jacob White on uranium stocks sell-off and the case for a recovery

    Nov 20, 20267 minAudio

    Sprott Asset Management Director of ETF Product Management Jacob White talked with Proactive's Stephen Gunnion about the sharp sell-off in uranium mining stocks, the disconnect with physical uranium prices and the...

    Credit the people on this episode

  3. Parbo Resources uncovers new greenstone belt at Mount Padbury

    Nov 20, 20266 minAudio

    Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone...

    Credit the people on this episode

  4. Arrow Exploration CEO on Icaco success, record production and next drilling targets

    Nov 19, 20264 minAudio

    Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded...

    Credit the people on this episode

  5. JURY ETF builds investor interest with its human rights-focused approach

    Nov 19, 20268 minAudio

    Jonny White, sales & client manager at Ethical Screening and senior advisor at The Justice Company, talked with Proactive's Stephen Gunnion about the first six months of the JURY Global High Dividend UCITS ETF...

    Credit the people on this episode